Aldosterone, organ damage and dietary salt

Clinical and Experimental Pharmacology and Physiology

Volumn 40, Issue 12, 2013, Pages 922-928

  Catena, Cristiana ^a   Colussi, Gianluca ^a   Sechi, Leonardo A ^a  

^a UNIVERSITY OF UDINE   (Italy)

Author keywords

Albuminuria; Aldosterone; Aldosterone antagonists; Heart; Hypertension; Hypertension endocrine; Hypertrophy; Kidney; Left ventricular function; Salt

Indexed keywords

ALBUMIN; ALDOSTERONE; AMLODIPINE; CREATININE; ENALAPRIL; EPLERENONE; GLUCOCORTICOID; HYDROCORTISONE; LOSARTAN; MINERALOCORTICOID RECEPTOR; PLACEBO; REACTIVE OXYGEN METABOLITE; SODIUM CHLORIDE; SPIRONOLACTONE;

ADRENALECTOMY; CARDIOVASCULAR MORTALITY; CREATININE BLOOD LEVEL; DIASTOLIC HEART FAILURE; DRUG EFFICACY; GLOMERULUS FILTRATION; HEART INJURY; HUMAN; HYPERTENSION; KIDNEY INJURY; OXIDATION REDUCTION POTENTIAL; PRIMARY HYPERALDOSTERONISM; PROTEIN URINE LEVEL; PROTEINURIA; REVIEW; SALT INTAKE; SYSTOLIC HEART FAILURE;

ALBUMINURIA; ALDOSTERONE; ALDOSTERONE ANTAGONISTS; HEART; HYPERTENSION; HYPERTENSION-ENDOCRINE; HYPERTROPHY; KIDNEY; LEFT VENTRICULAR FUNCTION; SALT;

ALDOSTERONE; ANIMALS; CARDIOVASCULAR DISEASES; HEART VENTRICLES; HUMANS; KIDNEY; MINERALOCORTICOID RECEPTOR ANTAGONISTS; RECEPTORS, MINERALOCORTICOID; SODIUM CHLORIDE, DIETARY;

EID: 84888051875     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/1440-1681.12145     Document Type: Review

References (79)

1. Marney AM, Brown NJ. Aldosterone and end-organ damage. Clin. Sci. 2007; 113267-78. 2.
2. Rossi GP, Sechi LA, Giacchetti G, Ronconi V, Strazzullo P, Funder JW. Primary aldosteronism: Cardiovascular, renal and metabolic implications. Trends Endocrinol. Metab. 2008; 19: 88-90.
3. Brilla CG, Weber KT. Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J. Lab. Clin. Med. 1992; 120: 893-901.
4. Rocha R, Rudolph AE, Frierdich GE, Nachowiak DA, Kekec BK, Blomme EA, McMahon EG, Delyani JA. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am. J. Physiol. Heart. Circ. Physiol. 2002; 283: H1802-10.
5. Martinez DV, Rocha R, Matsumura M, Oestreicher E, Ochoa-Maya M, Roubsanthisuk W, Williams GH, Adler GK. Cardiac damage prevention by eplerenone: Comparison with low sodium diet or potassium loading. Hypertension 2002; 39: 614-8.
6. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT Jr. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998; 31: 451-8.
7. Blasi ER, Rocha R, Rudolph AE, Blomme EA, Polly ML, McMahon EG. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int. 2003; 63: 1791-800.
8. Neves MF, Amiri F, Virdis A, Diep QN, Schiffrin EL; CIHR Multidisciplinary Research Group on Hypertension. Role of aldosterone in angiotensin II-induced cardiac and aortic inflammation, fibrosis, and hypertrophy. Can. J. Physiol. Pharmacol. 2005; 83: 999-1006.
9. Lacolley P, Labat C, Pujol A, Delcayre C, Benetos A, Safar M. Increased carotid wall elastic modulus and fibronectin in aldosterone-salt-treated rats: Effects of eplerenone. Circulation 2002; 106: 2848-53.
10. Cachofeiro V, Miana M, de Las Heras N, Martín-Fernández B, Ballesteros S, Fernández-Tresguerres J, Lahera V. Aldosterone and the vascular system. J. Steroid Biochem. Mol. Biol. 2008; 109: 331-5.
11. Sechi LA, Colussi GL, Di Fabio A, Catena C. Cardiovascular and renal damage in primary aldosteronism: Which outcomes after treatment. Am. J. Hypertens. 2010; 23: 1253-60.
12. Catena C, Colussi GL, Valeri M, Sechi LA. Association of aldosterone with left ventricular mass in hypertension: Interaction with plasma fibrinogen levels. Am. J. Hypertens. 2013; 26: 111-7.
13. Catena C, Colussi GL, Di Fabio A, Valeri M, Marzano L, Uzzau A, Sechi LA. Mineralocorticoid antagonists treatment versus surgery in primary aldosteronism. Horm. Metab. Res. 2010; 42: 440-5.
14. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 1999; 341: 709-17.
15. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 2003; 348: 1309-21.
16. Zannad F, McMurray JJV, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B. Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med. 2011; 364: 11-21.
17. Catena C, Colussi GL, Marzano L, Sechi LA. Aldosterone and the heart: From basic research to clinical evidence. Horm. Metab. Res. 2012; 44: 181-7.
18. Rizzoni D, Paiardi S, Rodella L, Porteri E, De Ciuceis C, Rezzani R, Boari GE, Zani F, Miclini M, Tiberio GA, Giulini SM, Agabiti-Rosei CA, Bianchi R, Agabiti-Rosei E. Changes in extracellular matrix in subcutaneous small resistance arteries of patients with primary aldosteronism. J. Clin. Endocrinol. Metab. 2006; 91: 2638-42.
19. Conn JW, Knopf RF, Nesbit RM. Clinical characteristics of primary aldosteronism from an analysis of 145 cases. Am. J. Surg. 1964; 107: 159-72.
20. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J. Am. Coll. Cardiol. 2005; 45: 1243-8.
21. Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, Lapenna R, Sechi LA. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch. Intern. Med. 2008; 168: 80-5.
22. Born-Frontsberg E, Reincke M, Rump LC, Hahner S, Diederich S, Lorenz R, Allolio B, Seufert J, Schirpenbach C, Beuschlein F, Bidlingmaier M, Endres S, Quinkler M. Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: Results of the German Conn's Registry. J. Clin. Endocrinol. Metab. 2009; 94: 1125-30.
23. Steichen O, Amar L, Plouin PF. Cardiovascular complications in patients with primary hyperaldosteronism: A controlled cross-sectional study. J. Hypertens. 2010; 1: (e-Supplement A1) e-301.
24. Strauch B, Petrák O, Wichterle D, Zelinka T, Holaj R, Widimsky J Jr. Increased arterial wall stiffness in primary aldosteronism in comparison with essential hypertension. Am. J. Hypertens. 2006; 19: 909-14.
25. Holaj R, Zelinka T, Wichterle D, Petrák O, Strauch B, Widimsky J Jr. Increased intima media thickness of the common carotid artery in primary aldosteronism in comparison with essential hypertension. J. Hypertens. 2007; 25: 1451-7.
26. Rossi GP, Rossi A, Zanin L, Calabró A, Crepaldi G, Pessina AC. Prevalence of extracranial carotid artery lesions at duplex in primary aldosteronism. Am. J. Hypertens. 1993; 6: 8-14.
27. Muiesan ML, Salvetti M, Paini A, Agabiti-Rosei C, Monteduro C, Galbassini G, Belotti E, Aggiusti C, Rizzoni D, Castellano M, Agabiti-Rosei E. Inappropriate left ventricular mass in patients with primary aldosteronism. Hypertension 2008; 52: 529-34.
28. Catena C, Colussi GL, Lapenna R, Nadalini E, Chiuch A, Gianfagna P, Sechi LA. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension 2007; 50: 911-8.
29. Rossi GP, Di Bello V, Ganzaroli C, Sacchetto A, Cesari M, Bertini A, Giorgi D, Scognamiglio R, Mariani M, Pessina AC. Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism. Hypertension 2002; 40: 23-7.
30. Catena C, Colussi GL, Marzano L, Sechi LA. Predictive factors of left ventricular mass changes after treatment of primary aldosteronism. Horm. Metab. Res. 2012; 44: 188-93.
31. Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B, Kleiman J, Krazuse S, Burns D, Williams GH. Effects of eplerenone, enalalpril, and eplerenone/enelapril in patients with essential hypertension and left ventricular hypertrophy: The 4E-left ventricular hypertrophy study. Circulation 2003; 108: 1831-8.
32. Mottram PM, Haluska B, Leano R, Cowley D, Stowasser M, Marwick TH. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation 2004; 110: 558-65.
33. Mak GJ, Ledwidge MT, Watson CJ, Phelan DM, Dawkins IR, Murphy NF, Patle AK, Baugh JA, McDonald KM. Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. J. Am. Coll. Cardiol. 2009; 54: 1674-82.
34. Edwards NC, Ferro CJ, Kirkwood H, Chue CD, Young AA, Stewart PM, Steeds RP, Townsends JN. Effect of spironolactone on left ventricular systolic and diastolic function in patients with early stage chronic kidney disease. Am. J. Cardiol. 2010; 106: 1505-11.
35. Gaddam K, Corros C, Pimenta E, Ahmed M, Denney T, Aban I, Inusah S, Gupta H, Lloyd SG, Oparil S, Husain A, Dell'Italia LJ, Calhoun DA. Rapid reversal of left ventricular hypertrophy and intracardiac volume overload in patients with resistant hypertension and hyperaldosteronism: A prospective clinical study. Hypertension 2010; 55: 1137-42.
36. Sechi LA, Colussi GL, Catena C. Hyperaldosteronism and left ventricular hypertrophy. Hypertension 2010; 56: e26.
37. Dabrowski R, Borowiec A, Smolis-Bak E, Kowalik I, Sosnowski C, Kraska A, Kazimierska B, Wozniak J, Zareba W, Szwed H. Effect combined spironolactone-β blocker±enalapril treatment on occurrence of symptomatic atrial fibrillation episodes in patients with a history of paroxysmal atrial fibrillation (SPIR-AF study). Am. J. Cardiol. 2010; 206: 1609-14.
38. Gao X, Peng L, Adhikari CM, Lin J, Zuo Z. Spironolactone reduced arrhythmia and maintained magnesium homeostasis in patients with congestive heart failure. J. Card. Fail. 2007; 13: 170-7.
39. Wei J, Ni J, Huang D, Chen M, Yan S, Peng Y. The effect of aldosterone antagonists for ventricular arrhythmia: A metaanalysis. Clin. Cardiol. 2010; 9: 572-7.
40. Nishimura M, Uzu T, Fujii T, Kuroda S, Nakamura S, Inenaga T, Kimura G. Cardiovascular complications in patients with primary aldosteronism. Am. J. Kidney Dis. 1999; 33: 261-6.
41. Danforth DN, Orlando MM, Bartter FC, Javadpour N. Renal changes in primary aldosteronism. J. Urol. 1977; 117: 140-4.
42. Beevers DG, Brown JJ, Ferriss JB, Fraser R, Lever AF, Robertson JI, Tree M. Renal abnormalities and vascular complications in primary hyperaldosteronism. Evidence on tertiary hyperaldosteronism. Q. J. Med. 1976; 45: 401-10.
43. Blumenfeld JD, Sealey JE, Schlussel Y, Vaughan ED, Sos TA, Atlas SA, Müller FB, Acevedo R, Ulick S, Laragh JH. Diagnosis and treatment of primary hyperaldosteronism. Ann. Intern. Med. 1994; 121: 877-85.
44. Rossi GP, Bernini G, Desideri G, Fabris B, Ferri C, Giacchetti G, Letizia C, Maccario M, Mannelli M, Matterello MJ, Montemurro D, Palumbo G, Rizzoni D, Rossi E, Pessina AC, Mantero F. Renal damage in primary aldosteronism: Results of the PAPY Study. Hypertension 2006; 48: 232-8.
45. Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, Lapenna R, Sechi LA. Relationships of plasma renin levels with renal function in patients with primary aldosteronism. Clin. J. Am. Soc. Nephrol. 2007; 2: 722-31.
46. Reincke M, Rump LC, Quinkler M, Hahner S, Diederich S, Lorenz R, Seufert J, Schirpenbach C, Beuschlein F, Bidlingmaier M, Meisinger C, Holle R, Endres S. Risk factors associated with a low glomerular filtration rate in primary aldosteronism. J. Clin. Endocrinol. Metab. 2009; 94: 869-75.
47. Ribstein J, Du Cailar G, Fesler P, Mimran A. Relative glomerular hyperfiltration in primary aldosteronism. J. Am. Soc. Nephrol. 2005; 16: 1320-5.
48. Sechi LA, Novello M, Lapenna R, Baroselli S, Nadalini E, Colussi GL, Catena C. Long-term renal outcomes in patients with primary aldosteronism. JAMA 2006; 295: 2638-45.
49. Kimura G, Saito F, Kojima S, Yoshimi H, Abe H, Kawano Y, Yoshida K, Ashida T, Kawamura M, Kuramochi M. Renal function curve in patients with secondary forms of hypertension. Hypertension 1987; 10: 11-5.
50. Wu VC, Kuo CC, Wang SM, Liu KL, Huang KH, Lin YH, Chu TS, Chang HW, Lin CY, Tsai CT, Lin LY, Chueh SC, Kao TW, Chen YM, Chiang WC, Tsai TJ, Ho YL, Lin SL, Wang WJ, Wu KD. Primary aldosteronism: Changes in cystatin C-based kidney filtration, proteinuria, and renal duplex indices with treatment. J. Hypertens. 2011; 29: 1778-86.
51. Wu VC, Yang SY, Lin JW, Cheng BW, Kuo CC, Tsai CT, Chu TS, Huang KH, Wang SM, Lin YH, Chiang CK, Chang HW, Lin CY, Lin LY, Chiu JS, Hu FC, Chueh SC, Ho YL, Liu KL, Lin SL, Yen RF, Wu KD. Kidney impairment in primary aldosteronism. Clin. Chim. Acta 2011; 412: 1319-25.
52. Sechi LA, Di Fabio A, Bazzocchi M, Uzzau A, Catena C. Intrarenal hemodynamics in primary aldosteronism before and after treatment. J. Clin. Endocrinol. Metab. 2009; 94: 1191-7.
53. Sechi LA, Catena C. The dual role of the kidney in primary aldosteronism: Key determinant in rescue from volume expansion and persistence of hypertension. Am. J. Kidney Dis. 2009; 54: 594-7.
54. Berl T, Katz FH, Henrich WL, de Torrente A, Schrier RW. Role of aldosterone in the control of sodium excretion in patients with advanced chronic renal failure. Kidney Int. 1978; 14: 228-35.
55. Hene RJ, Boer P, Koomans HA, Mees EJ. Plasma aldosterone concentrations in chronic renal disease. Kidney Int. 1982; 21: 98-101.
56. Quinkler M, Zehnder D, Eardley KS, Lepenies J, Howie AJ, Hughes SV, Cockwell P, Hewison M, Stewart PM. Increased expression of mineralocorticoid effector mechanisms in kidney biopsies of patients with heavy proteinuria. Circulation 2005; 112: 1435-43.
57. Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003; 41: 64-8.
58. Rossing K, Schjoedt KJ, Smidt UM, Boomsma F, Parving HH. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: A randomized, double-masked, cross-over study. Diabetes Care 2005; 28: 2106-12.
59. Epstein M, Williams GH, Weinberger M, Lewin A, Krause S, Mukherjee R, Patni R, Beckerman B. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin. J. Am. Soc. Nephrol. 2006; 1: 940-51.
60. Schjoedt KJ, Rossing K, Juhl TR, Boomsma F, Tarnow L, Rossing P, Parving HH. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int. 2006; 70: 536-42.
61. Bianchi S, Bigazzi R, Campese VM. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int. 2006; 70: 2116-23.
62. Chrysostomou A, Pedagogos E, MacGregor L, Becker GJ. Double blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clin. J. Am. Soc. Nephrol. 2006; 1: 256-62.
63. Furumatsu Y, Nagasawa Y, Tomida K, Mikami S, Kaneko T, Okada N, Tsubakihara Y, Imai E, Shoji T. Effect of renin-angiotensin-aldosterone system triple blockade on nondiabetic renal disease: Addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin converting enzyme inhibitor and angiotensin II receptor blocker. Hypertens. Res. 2008; 31: 59-67.
64. Tylicki L, Rutkowski P, Renke M, Larczynski W, Aleksandrowicz E, Lysiak-Szydlowska W, Rutkowski B. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: An open-label crossover randomized controlled trial. Am. J. Kidney Dis. 2008; 52: 486-93.
65. White WB, Duprez D, St Hillaire R, Krause S, Roniker B, Kuse- Hamilton J, Weber MA. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003; 41: 1021-6.
66. Williams GH, Burgess E, Kolloch RE, Ruilope LM, Niegowska J, Kipnes MS, Roniker B, Patrick JL, Krause SL. Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. Am. J. Cardiol. 2004; 93: 990-6.
67. Flack JM, Oparil S, Pratt JH, Roniker B, Garthwaite S, Kleiman JH, Yang Y, Krause SL, Workman D, Saunders E. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J. Am. Coll. Cardiol. 2003; 41: 1148-55.
68. Funder JW. Mineralocorticoid receptor activation and oxidative stress. Hypertension 2007; 50: 840-1.
69. Funder J, Myles K. Exclusion of corticosterone from epithelial mineralocorticoid receptors is insufficient for selectivity of aldosterone action: In vivo binding studies. Endocrinology 1996; 137: 5264-8.
70. Funder JW. Is aldosterone bad for the heart? Trends Endocrinol. Metab. 2004; 15: 139-42.
71. Hayashi H, Kobara M, Abe M, Tanaka N, Gouda E, Toba H, Yamada H, Tatsumi T, Nakata T, Matsubara H. Aldosterone nongenomically produces NADPH oxidase dependent reactive oxygen species and induces myocyte apoptosis. Hypertens. Res. 2008; 31: 363-75.
72. Fan C, Kawai Y, Inaba S, Arakawa K, Katsuyama M, Kajinami K, Yasuda T, Yabe- Nishimura C, Konoshita T, Miyamori I. Synergy of aldosterone and high salt induces vascular smooth muscle hypertrophy through up-regulation of NOX1. J. Steroid Biochem. Mol. Biol. 2008; 111: 29-36.
73. Luft FC, Fineberg NS, Sloan RS. Estimating dietary sodium intake in individuals receiving a randomly fluctuating intake. Hypertension 1982; 4: 805-8.
74. Jin Y, Kuznetsova T, Maillard M, Richart T, Thijs L, Bochud M, Herregods MC, Burnier M, Fagard R, Staessen JA. Independent relations of left ventricular structure with the 24-hour urinary excretion of sodium and aldosterone. Hypertension 2009; 54: 489-95.
75. Fox CS, Larson MG, Hwang SJ, Leip EP, Rifai N, Levy D, Benjamin EJ, Murabito JM, Meigs JB, Vasan RS. Cross-sectional relations of serum aldosterone and urine sodium excretion to urinary albumin excretion in a community-based sample. Kidney Int. 2006; 69: 2064-9.
76. du Cailar G, Fesler P, Ribstein J, Mimran A. Dietary sodium, aldosterone, and left ventricular mass changes during long-term inhibition of the renin-angiotensin system. Hypertension 2010; 56: 865-70.
77. Pimenta E, Gaddam KK, Pratt-Ubunama MN, Nishizaka MK, Aban I, Oparil S, Calhoun DA. Relation of dietary salt and aldosterone to urinary protein excretion in subjects with resistant hypertension. Hypertension 2008; 51: 339-44.
78. Pimenta E, Gordon RD, Ahmed AH, Cowley D, Leano R, Marwick TH, Stowasser M. Cardiac dimensions are largely determined by dietary salt in patients with primary aldosteronism: Results of a case-control study. J. Clin. Endocrinol. Metab. 2011; 26: 2813-20.
79. Colussi GL, Catena C, Sechi LA. Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension. J. Hypertens. 2013; 31: 3-15.